DNA methylation as a clinical marker in oncology

Journal of Clinical Oncology

Volumn 30, Issue 20, 2012, Pages 2566-2568

  Issa, Jean Pierre ^a  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HISTONE ACETYLTRANSFERASE; HISTONE DEACETYLASE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; MICRORNA; PROTEIN KINASE ZAP 70; RNA POLYMERASE;

CANCER PROGNOSIS; CHRONIC LYMPHATIC LEUKEMIA; CPG ISLAND; DNA METHYLATION; DNA SEQUENCE; EPIGENETICS; FLOW CYTOMETRY; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENOMICS; HUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN ANALYSIS; SHORT SURVEY; STABLE EXPRESSION; TREATMENT RESPONSE;

DNA METHYLATION; HUMANS; NEOPLASMS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84864070193     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.42.1016     Document Type: Short Survey

References (19)

1. Harbeck N, Salem M, Nitz U, et al: Personalized treatment of early-stage breast cancer: Present concepts and future directions. Cancer Treat Rev 36:584-594, 2010
2. Estey EH: Prognostic factors in acute myelogenous leukemia. Leukemia 15:670-672, 2001
3. Stratton MR: Exploring the genomes of cancer cells: Progress and promise. Science 331:1553-1558, 2011
4. Claus R, Lucas DM, Stilgenbauer S, et al: Quantitative DNA methylation analysis identifies a single CpG dinucleotide important for ZAP-70 expression and predictive of prognosis in chronic lymphocytic leukemia. J Clin Oncol 30:2483-2491, 2012
5. Bird A: DNA methylation patterns and epigenetic memory. Genes Dev 16:6-21, 2002
6. Markl ID, Cheng J, Liang G, et al: Global and gene-specific epigenetic patterns in human bladder cancer genomes are relatively stable in vivo and in vitro over time. Cancer Res 61:5875-5884, 2001 (Pubitemid 32771343)
7. Raynal NJ, Si J, Taby RF, et al: DNA methylation does not stably lock gene expression but instead serves as a molecular mark for gene silencing memory. Cancer Res 72:1170-1181, 2012
8. Eldar A, Elowitz MB: Functional roles for noise in genetic circuits. Nature 467:167-173, 2010
9. Hegi ME, Diserens AC, Gorlia T, et al: MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352:997-1003, 2005 (Pubitemid 40349502)
10. Karayan-Tapon L, Quillien V, Guilhot J, et al: Prognostic value of O6-methylguanine-DNA methyl-transferase status in glioblastoma patients, assessed by five different methods. J Neurooncol 97:311-322, 2010
11. Toyota M, Ahuja N, Ohe-Toyota M, et al: CpG Island Methylator Phenotype in Colorectal Cancer. Proc Natl Acad Sci U S A 96:8681-8686, 1999 (Pubitemid 29354851)
12. Issa JP: CpG island methylator phenotype in cancer. Nat Rev Cancer 4:988-993, 2004
13. Noushmehr H, Weisenberger DJ, Diefes K, et al: Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell 17:510-522, 2010
14. Fang F, Turcan S, Rimner A, et al: Breast cancer methylomes establish an epigenomic foundation for metastasis. Sci Transl Med 3:75ra25, 2011
15. Issa JP, Kantarjian HM: Targeting DNA methylation. Clin Cancer Res 15:3938-3946, 2009
16. Stewart DJ, Issa JP, Kurzrock R, et al: Decitabine effect on tumor global DNA methylation and other parameters in a phase I trial in refractory solid tumors and lymphomas. Clin Cancer Res 15:3881-3888, 2009
17. Kantarjian H, Oki Y, Garcia-Manero G, et al: Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood 109:52-57, 2007 (Pubitemid 46053042)
18. Shen L, Kantarjian H, Guo Y, et al: DNA methylation predicts survival and response to therapy in patients with myelodysplastic syndromes. J Clin Oncol 28:605-613, 2010
19. Taby R, Issa JP: Cancer epigenetics. CA Cancer J Clin 60:376-392, 2010